"Janus Kinase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is involved in signaling from a broad variety of CYTOKINE RECEPTORS.
| Descriptor ID |
D053613
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.100 D12.776.476.393.100
|
| Concept/Terms |
Janus Kinase 1- Janus Kinase 1
- JAK-1 Protein Tyrosine Kinase
- JAK 1 Protein Tyrosine Kinase
- JAK1 Protein Tyrosine Kinase
- Jak1 Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 1".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 1".
This graph shows the total number of publications written about "Janus Kinase 1" by people in this website by year, and whether "Janus Kinase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase 1" by people in Profiles.
-
Individuals with JAK1 variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis. J Exp Med. 2024 Jun 03; 221(6).
-
Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis. JAMA. 2019 07 23; 322(4):309-311.
-
Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia. Oncogene. 2018 02 22; 37(8):1107-1118.
-
CUZD1 is a critical mediator of the JAK/STAT5 signaling pathway that controls mammary gland development during pregnancy. PLoS Genet. 2017 Mar; 13(3):e1006654.
-
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6.
-
Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014 Aug 28; 124(9):1460-72.
-
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther. 2012 Oct; 11(10):2254-64.
-
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9.
-
Three lysine residues in the common ? chain of the interleukin-5 receptor are required for Janus kinase (JAK)-dependent receptor ubiquitination, endocytosis, and signaling. J Biol Chem. 2011 Nov 18; 286(46):40091-103.
-
Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia. 2011 Aug; 25(8):1365-8.